Seaport will use the funds for its neuropsychiatric drug pipeline, while Hemab will focus on bleeding disorder medicines. Seaport will use the funds for its neuropsychiatric drug pipeline, while Hemab will focus on bleeding disorder medicines. ... The value of IPOs so far this year suggests the sector is winning the battle against macroeconomic policy shifts in the US. Credit: Billion Photos/Shutterstock.com. Seaport Therapeutics and Hemab Therapeutics have both outlined pricings for their respective initial public offerings (IPOs), adding to an already busy month for biotechs making the public jump. Sutacimig, also known as HMB-001, is set to command most of the IPO funds. Around $120m will be put towards the asset’s clinical development in the two bleeding disorders. Around $60m will be used to advance clinical development of HMB-002, the biotech’s monovalent antibody in Phase I/II development for the subcutaneous prophylactic treatment of Von Willebrand Disease. GlyphAllo, also known as SPT-300, has been designed using Seaport’s Glyph platform, which the biotech says overcomes bioavailability and first-pass metabolism limitations. These hurdles have historically plagued treatments targeted against neuropsychiatric disorders. Seaport’s platform employs the lymphatic system’s natural lipid absorption and transport process to bypass the liver, which should also help reduce hepatotoxicity. Around $121m of the IPO raise will help fund GlyphAllo through a Phase IIb trial (NCT07065240) and into Phase III development. Seaport, a biotech developing treatments in the neuropsychiatric space, is offering 11.8 million shares priced between $16 and $18 each on the Nasdaq. If the IPO settles in the midpoint of this range, the biotech estimates net proceeds of $183.5m, which could rise by a further $27.9m based on the underwriters’ option.